OmniAb and Veraxa Biotech Partner on Solid Tumor Drug Discovery Program

OmniAb, Inc. and Veraxa Biotech are partnering on a solid tumor drug discovery program. OmniAb offers a discovery platform that uses transgenic animals to generate diverse antibodies for next-generation therapeutics. The platform includes OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, and OmniTaur, each with unique features for different therapeutic applications. The partnership aims to leverage OmniAb's technology to discover new drugs for solid tumors.

OmniAb, Inc. and Veraxa Biotech have entered into a strategic co-discovery alliance to develop a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors. The collaboration leverages OmniAb's transgenic antibody discovery platform, which includes OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, and OmniTaur, each offering unique features for different therapeutic applications. This partnership aims to harness OmniAb's technology to discover new drugs for solid tumors [1].

Under the terms of the agreement, Veraxa will initiate a novel bsADC program addressing two attractive target molecules in cancer medicine. The company will utilize OmniAb's suite of transgenic antibody discovery solutions to source high-quality human antibody leads, which are naturally optimized through in vivo affinity maturation. Veraxa will establish the bsADC lead candidate by applying its proprietary linker technology and conjugation routine, and will be responsible for preclinical validation. The resulting bsADC program will be jointly owned by both parties, with shared revenues from the program's continued development, licensing, and commercialization [1].

Christoph Antz, Ph.D., CEO and Co-Founder of Veraxa, commented, "Bispecific ADCs represent a powerful opportunity to address difficult-to-treat solid tumors, and this collaboration fits squarely within our mission to drive innovation through targeted partnerships. Strategic collaborations will continue to be a mainstay in Veraxa's pipeline growth strategy, and today’s announcement marks the second major initiative within the past six months, following our first radiopharmaceutical alliance late last year. We look forward to advancing this discovery program alongside OmniAb and deliver novel therapeutic solutions for patients with significant unmet needs" [1].

This partnership underscores the growing trend of strategic collaborations in the biopharmaceutical industry, where companies combine their expertise to accelerate drug discovery and development. The alliance between OmniAb and Veraxa is a significant step forward in the quest to develop effective treatments for solid tumors.

References:
[1] https://www.contractpharma.com/breaking-news/veraxa-biotech-enters-co-discovery-alliance-with-omniab/
[2] https://www.tradingview.com/news/reuters.com,2025-05-05:newsml_GNX8DBgb3:0-veraxa-biotech-enters-co-discovery-alliance-with-omniab-for-a-novel-bispecific-antibody-drug-conjugate-program/